Critical Limb Ischemia (CLI) Clinical Trial
Official title:
LIFE-BTK (pivotaL Investigation of saFety and Efficacy of BRS Treatment-Below The Knee) Randomized Controlled Trial
The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be randomized in a 2:1 ratio. The clinical investigation will be conducted at approximately 65 clinical sites in the US, Asia, Australia, and New Zealand.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02287974 -
Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03006770 -
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
|
Phase 3 | |
| Completed |
NCT00987363 -
Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02538978 -
Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
|
Phase 3 | |
| Completed |
NCT01408381 -
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).
|
Phase 2 | |
| Active, not recruiting |
NCT05208905 -
LIFE-BTK PK Sub-study
|
N/A | |
| Recruiting |
NCT04849325 -
IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease
|
N/A | |
| Completed |
NCT01257776 -
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT03111238 -
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
|
Phase 3 | |
| Terminated |
NCT03174522 -
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
|
Phase 3 | |
| Completed |
NCT01386216 -
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)
|
Phase 1 | |
| Available |
NCT03746899 -
Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)
|
||
| Available |
NCT03886506 -
Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
|